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Aims Recently it has been shown that the mitochondria-targeted S-nitrosothiol MitoSNO protects against acute
ischaemia/reperfusion (IR) injury by inhibiting the reactivation of mitochondrial complex I in the first minutes of
reperfusion of ischaemic tissue, thereby preventing free radical formation that underlies IR injury. However, it remains
unclear how this transient inhibition of mitochondrial complex I-mediated free radicals at reperfusion affects the
long-term recovery of the heart following IR injury. Here we determined whether the acute protection by MitoSNO
at reperfusion prevented the subsequent development of post-myocardial infarction heart failure.
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Methods
and results
Mice were subjected to 30 min left coronary artery occlusion followed by reperfusion and recovery over 28
days. MitoSNO (100 ng/kg) was applied 5 min before the onset of reperfusion followed by 20 min infusion
(1 ng/kg/min). Infarct size and cardiac function were measured by magnetic resonance imaging (MRI) 24 h after
infarction. MitoSNO-treated mice exhibited reduced infarct size and preserved function. In addition, MitoSNO at
reperfusion improved outcome measures 28 days post-IR, including preserved systolic function (63.7 ±1.8% LVEF vs.
53.7 ± 2.1% in controls, P = 0.01) and tissue fibrosis.
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Conclusions MitoSNO action acutely at reperfusion reduces infarct size and protects from post-myocardial infarction heart failure.
Therefore, targeted inhibition of mitochondrial complex I in the first minutes of reperfusion by MitoSNO is a rational
therapeutic strategy for preventing subsequent heart failure in patients undergoing IR injury.
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Introduction
During myocardial infarction (MI), mitochondria are central to
mediating the damage that underlies ischaemia/reperfusion (IR)
injury.1–3 In particular, mitochondrial reactive oxygen species
(ROS) production in conjunction with mitochondrial matrix
Ca2+ overload converge to induce opening of the mitochondrial












. permeability transition pore, which is thought to drive a significant
amount of acute damage.4 Therefore, decreasing ROS production
by mitochondria upon reperfusion is an appealing therapeutic
strategy to minimize IR injury.
Among the agents that protect against IR injury are nitric oxide
(NO) and its metabolites,5–8 but clinical use has been limited by
their pleiotropic action and uncertainty regarding their cardiopro-
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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tective targets and mechanism(s). However, recently we developed
a mitochondria-targeted S-nitrosothiol (MitoSNO) to elucidate a
critical cardioprotective mechanism mediated specifically by mito-
chondrial S-nitrosation.9,10
We identified an essential component of MitoSNO-mediated
protection to be due to the reversible S-nitrosation of a critical
functional cysteine, Cys39 on the ND3 subunit of mitochondrial
complex I, which only becomes susceptible to modification fol-
lowing prolonged ischaemia.11 This transient modification inhibits
rapid reactivation of mitochondrial complex I during reperfusion,
thereby preventing mitochondrial ROS production. Through this
acutely acting mechanism, MitoSNO systemically prevented acute
cardiac IR injury. This suggested that MitoSNO could be used to
decrease cardiac IR injury in a range of pathological situations, as
it is very rapidly taken up from the circulation into heart mito-
chondria upon i.v. administration during the reperfusion phase
of IR injury, does not affect non-ischaemic tissue, and its inhi-
bition of complex I is rapidly reversed after a few minutes of
reperfusion. These effects were in stark contrast to induction
of non-mitochondrial S-nitrosation, which has been shown to be
insufficient to mitigate mitochondrial ROS and protect against
reperfusion injury in vivo.11 However, to be a useful therapeutic
strategy, the selective S-nitrosation of complex I must lead to an
improved prognosis for the patient by decreasing the amount of
long-term cardiac tissue damage and organ dysfunction that are fre-
quent consequences of an IR injury and which lead on to chronic
heart disease.
Therefore, the aim of this study was to determine whether the
acute and transient action of MitoSNO during reperfusion of the
ischaemic heart would protect against the chronic and persistent
organ damage that leads to post-MI heart disease and failure. We
hypothesized that the burst of ROS emanating from the rapid
reactivation of mitochondrial complex I during reperfusion drives
the initial acute damage to the heart that leads over time to the
development of subsequent heart failure. Therefore, prevention
of acute ROS production by complex I during reperfusion by
MitoSNO would not only decrease acute IR injury but would also
protect the heart from post-MI heart damage and dysfunction




























































In vivo mouse model of myocardial
infarction
Infarct size following IR in an in situ open chest mouse model was
measured as previously described.12
Magnetic resonance imaging
Cardiac late gadolinium-enhanced magnetic resonance imaging
(LGE-MRI) and cine MRI were performed as recently described.12
Results and Discussion
Protection against cardiac ischaemia/
reperfusion injury by administration
of mitochondria-targeted S-nitrosothiol
at reperfusion
We have recently demonstrated that administration of the
mitochondria-selective S-nitrosating agent MitoSNO decreases
acute cardiac IR injury by S-nitrosation of proteins within
mitochondria, and that this protection is primarily due to the
functional S-nitrosation of Cys39 on the ND3 subunit of com-
plex I that decreases mitochondrial superoxide production upon
reperfusion.11 However, for this approach to be useful clinically it
is important to show that the acute protective action of MitoSNO
extended into the long term.
An important observation from our previous work was that
MitoSNO is only effective when it is perfused into ischaemic tissue,
as protective inhibition of complex I by S-nitrosation of ND3 Cys39
can only be achieved in this setting.11 As it is well established
that reperfusion of ischaemic tissue in the clinic leads to variable
rates of reintroduction of blood supply, we modified our treatment
protocol combining a bolus injection with persistent perfusion
over 20 min to ensure delivery of active MitoSNO to all parts of
the tissue as reperfusion progressed. This protocol is summarized
in Figure 1: mice were subjected to 30 min LAD occlusion, and
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Figure 1 Schematic diagram of experimental protocols and measurements. Summary of the mitochondria-targeted S-nitrosothiol (MitoSNO)
treatment protocol applied to the mouse LAD occlusion model as well as timing and the parameters measured. He, haemodynamic parameters;
MRI, magnetic resonance imaging; Path, time of sacrifice for histopathology; Trop, troponin.
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Effects of mitochondria-targeted S-nitrosothiol (MitoSNO) on infarct size and heart function 24 h post-myocadial infarction (MI).
(A) Representative heart cross-sections for infarct size assessment via histological 2,3,5-triphenyltetrazolium chloride (TTC) staining. (B)
Quantification of TTC-stained infarcts. (C) Quantification of troponin I level in blood serum mirrored 24 h post-MI. (D) The infarct size
quantification by late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) 24 h post-MI for the MitoSNO-treated group compared
with the untreated control group including representative images. (E) Assessment of LVEF 24 h post-MI. **P < 0.001; *P < 0.05.
then administered MitoSNO as a systemic i.v. bolus followed by
continuous infusion beginning 5 min before reperfusion. A series
of measures of heart function were applied over the subsequent 4
weeks to assess whether this treatment improved the long-term
recovery of the heart.
Mitochondria-targeted S-nitrosothiol
at reperfusion reduces infarct size
and troponin release assessed 24 h
post-myocardial infarction
We first assessed whether this MitoSNO administration protocol
protected against heart tissue damage measured by 2,3,5-triphenyl
tetrazolium chloride (TTC) staining 24 h post-reperfusion
(Figure 2A). This showed that a systemic i.v. bolus and infusion of
MitoSNO beginning 5 min before reperfusion resulted in a sig-
nificant reduction in infarct size (Figure 2B) as well as significantly
lower values of the clinically used marker, serum troponin I, 24 h
post-MI in the MitoSNO-treated group (Figure 2C).
In addition, cardiac LGE-MRI 24 h post-MI confirmed drastically
































. treatment (Figure 2D; Supplementary material online, Videos S1a
and S2a), as well as increased post-MI LV function (Figure 2E).
Numerical data of MRI analyses are provided in Supplementary
material online, Table S1. These findings indicate that MitoSNO
affords robust protection against IR injury as assessed by clinically
relevant measures 24 h post-MI.
Lack of effect of mitochondria-targeted
S-nitrosothiol on haemodynamic
parameters
A concern in the use of all NO-based drugs is that release of
free NO may result in alterations to blood pressure or haemo-
dynamics that can preclude their clinical use. This should not be a
concern with MitoSNO as it is rapidly taken up into mitochondria
within tissues where it transfers a nitrosonium moiety directly to
mitochondrial thiols, with negligible release of free NO at thera-
peutic concentrations.11,13 In addition, we have recently demon-
strated that MitoSNO acts independently of non-mitochondrial
cGMP pathways, and that an acute dose of MitoSNO has no effect
on haemodynamics in a normally respiring heart.11,13 However, the
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Haemodynamic effect of mitochondria-targeted S-nitrosothiol (MitoSNO). LV catheterization was used to obtain blood pressure
data during infarct size measurement in the acute model of 30 min ischaemia followed by 2 h reperfusion, comparing MitoSNO treatment with
controls. Haemodynamic parameters: (A) systolic blood pressure; (B) dP/dtmax; and (C) heart rate were determined and plotted as changes to
baseline. n = 7.
possibility remains that the administration of MitoSNO during IR
injury may alter haemodynamics, in addition to the possibility that
continuous infusion of MitoSNO may disrupt haemodynamics while
an acute bolus alone did not. To assess both of these possibilities,
blood pressure and heart function measurements were taken at
all stages of acute MI and subsequent reperfusion via LV catheter-
ization, and the effects of MitoSNO administration and infusion
on these were assessed for up to 2 h post-reperfusion (Figure 3).
We observed no difference in systolic blood pressure between
the MitoSNO-treated and vehicle-treated groups (Figure 3A). In
addition, MitoSNO also had no effect on dP/dtmax (Figure 3B) or
heart rate (Figure 3C). Together, these data confirmed that a dos-
ing regimen of MitoSNO that was robustly cardioprotective and
which included continual infusion for 20 min had no effect on
haemodynamics or blood pressure. Therefore, MitoSNO can be
administered as a bolus followed by continual infusion systemically
at cardioprotective levels without affecting haemodynamics, which
avoids a major limitation that restricts the use of other cardiopro-






























given at reperfusion protects from
long-term post-myocardial infarction
heart failure and myocardial fibrosis
The above data show that this dosing regimen of MitoSNO pro-
tects heart function against IR damage when measured 24 h after
reperfusion. However, a common consequence of IR injury in MI
is the subsequent long-term development of heart dysfunction
and damage, and it was unknown whether MitoSNO—which acts
only in the first minutes of reperfusion—could impact on these
long-term sequelae. To see if MitoSNO treatment at reperfusion
afforded long-term protection, we assessed how well heart damage
resolved over 28 days.
Determination of LVEF indicated significant improvement in the
heart function of MitoSNO-treated mice compared with controls
28 days post-MI (Figure 4A; Supplementary material online, Videos
S1b and S2b). In addition, measurement of tissue fibrotic remod-
elling 28 days post-MI showed a significant decrease in collagen
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.












































Figure 4 Heart function and damage measured 28 days post-myocardial infarction (MI). (A) Assessment of LVEF 28 days post-MI. (B)
Representative heart slices after Masson trichrome staining of control and mitochondria-targeted S-nitrosothiol (MitoSNO)-treated hearts.
(C) Quantification of collagen content in total heart comparing MitoSNO and control hearts. *P < 0.01; **P < 0.001.
content in the MitoSNO-treated hearts compared with the con-
trol hearts (Figure 4B and C). Therefore, acute administration of
MitoSNO upon reperfusion not only decreased acute heart dam-
age but also led to an improved long-term functional outcome for
the heart. These results are particularly striking in the context
of our recent characterization of the kinetics of MitoSNO activ-
ity at reperfusion in vivo.11 Intravenous administration of MitoSNO
results in mitochondrial S-nitrosation activity only in the first min-
utes of reperfusion, which is essential and necessary to mitigate
mitochondrial ROS through mitochondrial complex I, and conse-
quent initiation of acute cell death.11 With the findings described
herein, this transient MitoSNO activity is clearly also critical for
long-term recovery of the heart post-reperfusion.
Conclusion
Although recent years have seen an increase in survival after
an acute MI, the long-term implications of cardiac IR injury
with the development of chronic heart failure remain. Here we
find MitoSNO to be a highly promising and clinically applicable
cardioprotective therapy, which could be applied acutely after an
infarct and would protect the heart not only against acute damage
but also against long-term injury. Furthermore, with previous eluci-
dation of the mechanism of MitoSNO action, here we demonstrate
that transient MitoSNO action in the first minutes of reperfusion is
sufficient to protect from long-term post-MI sequelae. Additionally,








































. the hindering side effects of generalized NO therapy are not
present, facilitating the translation into vulnerable MI patients.
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